The combination of ibrutinib and venetoclax is a viable treatment option for patients with CLL, according to new research presented at ASH 2019. Professor Constantine Tam, from the Peter MacCallum Cancer Centre in Melbourne, presented the findings of the international multicentre CAPTIVATE study. He told delegates that the combination of ibrutinib and venetoclax had previously ...
Ibrutinib and venetoclax: an all oral, all novel, chemo-free combo for CLL
By Mardi Chapman
10 Dec 2019